These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2996448)

  • 21. [Free amino acids in normal and carcinomatous ovarian tissue in correlation with serum level--tumor diagnostic possibilities].
    Elling D; Bader K
    Zentralbl Gynakol; 1987; 109(16):1013-22. PubMed ID: 3673322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours.
    Burger HG; Robertson DM; Cahir N; Mamers P; Healy DL; Jobling T; Groome N
    Clin Endocrinol (Oxf); 1996 Apr; 44(4):413-8. PubMed ID: 8706307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LyGDI is a promising biomarker for ovarian cancer.
    Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
    Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study.
    Zhu GG; Stenbäck F; Risteli L; Risteli J; Kauppila A
    Cancer; 1993 Sep; 72(5):1679-84. PubMed ID: 8348501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen production by epithelial ovarian tumours in post-menopausal women.
    Heinonen PK
    Maturitas; 1991 Jun; 13(2):117-22. PubMed ID: 1921734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 27. The hypercoagulable state and pulmonary embolism in patients with ovarian carcinoma.
    Planner RS; O'Sullivan EF; Campbell JJ; Ball DL
    Aust N Z J Obstet Gynaecol; 1978 Aug; 18(3):209-12. PubMed ID: 217329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibin and ovarian cancer].
    Burger HG; Baillie A; Drummond AE; Healy DL; Jobling T; Mamers P; Robertson DM; Susil B; Cahir N; Shen Y; Verity K; Fuller PJ; Groome NP; Findlay JK
    Vopr Onkol; 1999; 45(4):369-73. PubMed ID: 10532093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of serum micronutrients and ovarian cancer.
    Helzlsouer KJ; Alberg AJ; Norkus EP; Morris JS; Hoffman SC; Comstock GW
    J Natl Cancer Inst; 1996 Jan; 88(1):32-7. PubMed ID: 8847723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Appendiceal Lesions in Appendicectomies Performed During Surgery for Mucinous Ovarian Tumors: A Retrospective Study.
    Moore L; Gajjar K; Jimenez-Linan M; Crawford R
    Int J Gynecol Cancer; 2016 Oct; 26(8):1386-9. PubMed ID: 27552403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
    Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
    Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.
    Puls LE; Powell DE; DePriest PD; Gallion HH; Hunter JE; Kryscio RJ; van Nagell JR
    Gynecol Oncol; 1992 Oct; 47(1):53-7. PubMed ID: 1427402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
    Noguchi T; Kitawaki J; Tamura T; Kim T; Kanno H; Yamamoto T; Okada H
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):657-60. PubMed ID: 8476778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
    Yoshida A; Sarian LO; Andrade LA; Pignataro F; Pinto GA; Derchain SF
    Int J Gynecol Cancer; 2007; 17(3):607-14. PubMed ID: 17504375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accuracy of intraoperative frozen section for the evaluation of ovarian neoplasms: an institutional experience.
    Hashmi AA; Naz S; Edhi MM; Faridi N; Hussain SD; Mumtaz S; Khan M
    World J Surg Oncol; 2016 Mar; 14():91. PubMed ID: 27029917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
    Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
    Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.